Pitocin or Oral Misoprostol for PROM IOL (POM PROM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04028765|
Recruitment Status : Recruiting
First Posted : July 23, 2019
Last Update Posted : August 15, 2019
|Condition or disease||Intervention/treatment||Phase|
|PROM||Drug: Misoprostol Drug: Oxytocin||Phase 4|
Premature rupture of membranes (PROM) occurs in approximately 8% of pregnancies at term.1 Although onset of spontaneous labor is often prompt after membrane rupture, a delay from PROM to labor is associated with an increased risk of intrauterine infection and its associated maternal and fetal complications. For this reason, ACOG endorses induction of labor for PROM "if spontaneous labor does not occur near the time of presentation."
The optimal method for PROM induction is less clear. Prior literature has examined the use of Pitocin (Oxytocin), vaginal and oral misoprostol, and dinoprost with mixed results. The TermPROM study found an increased risk of chorioamnionitis and NICU admission among women treated with vaginal misoprostol for induction.
The postulated link between vaginal misoprostol and chorioamnionitis is the need for vaginal examination for placement of the misoprostol; more vaginal examinations could potentially increase the risk for infection. Utilizing oral misoprostol would eliminate the need for a vaginal exam for administration, thereby potentially mitigating this risk of infection. Currently, vaginal and oral misoprostol as well as oxytocin are used routinely in clinical care based on provider discretion.
Among 7 randomized controlled trials examining the use of oral misoprostol as compared to oxytocin, two found oral misoprostol to result in faster induction to delivery, two found oxytocin to result in faster deliveries, and the remaining three found no difference between the two.3-9 These studies are limited by small sample size, inadequate reporting of patient demographics, varied misoprostol and oxytocin protocols, and inconsistent primary outcomes. Therefore, the utility of oral misoprostol in this population has not been established. Furthermore, its efficacy in specific patient populations is unreported in the literature.
The primary aim of this study is to determine if oxytocin or oral misoprostol results in a shorter interval to delivery after the start of induction among nulliparous women with unfavorable cervical exams with PROM.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||155 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||POM PROM: Pitocin or Oral Misoprostol for PROM IOL in Nulliparous Women With Unfavorable Cervical Exams|
|Actual Study Start Date :||August 12, 2019|
|Estimated Primary Completion Date :||August 30, 2021|
|Estimated Study Completion Date :||September 30, 2021|
Active Comparator: Oral Misoprostol
Oral misoprostol 50 mcg q4H for up to 6 doses or until cervical ripening is no longer indicated
Active Comparator: Oxytocin
IV Oxytocin 2mU/min, increased by 2mU/min q15 minutes per hospital protocol
- Time from IOL to delivery [ Time Frame: Enrollment to Delivery ]Time (hours) from start of IOL to delivery
- Infection [ Time Frame: Enrollment to Delivery ]Suspected intraamniotic infection
- Time from PROM to delivery [ Time Frame: Enrollment to Delivery ]Time (hours) from PROM to delivery
- Time from IOL to vaginal delivery [ Time Frame: Enrollment to Delivery ]Time (hours) from PROM to delivery
- Time from PROM to vaginal delivery [ Time Frame: Enrollment to Delivery ]Time (hours) from PROM to vaginal delivery
- Cesarean delivery [ Time Frame: Enrollment to Delivery ]Cesarean section rate
- Maternal morbidity [ Time Frame: Enrollment to 1 week postpartum ]Composite maternal morbidity: postpartum hemorrhage, blood transfusion, endometritis, wound infection, VTE, hysterectomy, ICU admission, readmission within 1 week, death
- Neonatal Morbidity [ Time Frame: Enrollment to 1 week postpartum ]Composite neonatal morbidity: Neonatal intensive care (ICN) admission > 48 hours, neonatal blood transfusion, hypoxic ischemic encephalopathy, intraventricular hemorrhage grade III or IV, headcooling, severe respiratory distress syndrome, necrotizing enterocolitis, sepsis, death
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04028765
|Contact: Whitney R Bender, MDfirstname.lastname@example.org|
|United States, Pennsylvania|
|Hospital of the University of Pennsylvania||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Whitney R Bender, MD 434-294-8416 email@example.com|